Published in Nouv Presse Med on October 22, 1979
From raw materials to validated system: the construction of a genomic library and microarray to interpret systemic perturbations in Northern bobwhite. Physiol Genomics (2010) 0.96
A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy. Transl Oncol (2013) 0.81
The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis. Cancers (Basel) (2011) 0.75
Interaction of tissue factor and factor VII at the earliest phase of coagulation. Thromb Diath Haemorrh Suppl (1965) 1.02
Intravascular coagulation and heparin therapy in acute renal failure: a reappraisal. Rev Eur Etud Clin Biol (1973) 1.01
[Various molecular states of factor II (prothrombin). Their study by means of staphylocoagulase and anti-factor II antibodies. I. Factor II in patients treated with vitamin K antagonists]. Thromb Diath Haemorrh (1968) 0.99
Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thromb Diath Haemorrh (1970) 0.99
[Coagulation factor VII deficiency in 3 patients with trisomy 8]. Ann Genet (1974) 0.94
[Antiproteinase activity of alpha-2-macroglobulin. II. Its role in progressive antithrombin states]. Rev Fr Etud Clin Biol (1968) 0.93
Alpha-2-macroglobulin as progressive antithrombin. Nature (1967) 0.90
Evolution of blood clotting factor leves in premature infants during the first 10 days of life: a study of 96 cases with comparison between clinical status and blood clotting factor levels. Pediatr Res (1973) 0.86
Antibody-induced von Willebrand syndrome: inhibition of VIII VWF and VIII AGN with sparing of VIII AHF by the autoantibody. Am J Hematol (1978) 0.83
Tissue factor activity of cultured human lymphocytes. Biomedicine (1975) 0.82
The procoagulant factor of leukaemic promyelocytes: demonstration of immunologic cross reactivity with human brain tissue factor. Br J Haematol (1975) 0.80
Congenital abnormality of the prothrombin molecule (factor II) in four siblings: prothrombin Barcelona. Blood (1971) 0.80
[Immunologic study of human prothrombin and thrombin]. Thromb Diath Haemorrh (1967) 0.79
[Survival in man of radioactive iodine labelled prothrombin (I-131)]. Rev Fr Transfus (1968) 0.79
Antithrombin III versus prothrombin in liver cirrhosis. Haemostasis (1981) 0.79
Abnormal activation of a human prothrombin variant: prothrombin Barcelona. FEBS Lett (1978) 0.77
Purification and partial characterization of a new variant of human prothrombin: prothrombin Metz. FEBS Lett (1979) 0.77
Albumin, fibrinogen, prothrombin and antithrombin III variations in blood, urines and liver in rat nephrotic syndrome (Heymann nephritis). Thromb Haemost (1983) 0.75
[Analytic study of coagulation on microsamples of capillary blood]. Pathol Biol (Paris) (1972) 0.75
[Circulating anticoagulants in hemophilia]. Rev Fr Transfus (1972) 0.75
[Can one treat intravascular thromboses with thrombolytics without risk?]. Presse Med (1968) 0.75
[Severe blood coagulation disorder as the first sign of a peritoneal hemangio-endothelioma: a new therapeutic approach (author's transl)]. Arch Fr Pediatr (1980) 0.75
[What are the current indications for lymphography?]. Presse Med (1968) 0.75
[Familial thromboembolic disease associated with antithrombin III deficiency (author's transl)]. Ann Med Interne (Paris) (1980) 0.75
[Relative incidence of constitutional hemorrhagic syndromes]. Bull Inst Natl Sante Rech Med (1968) 0.75
[Attempted treatment of renal vascular obstruction by streptokinase in 2 anuric patients]. Ann Med Interne (Paris) (1969) 0.75
[Severe epistaxis in hemorrhagic syndromes (excepting Rendu-Osler disease)]. Ann Otolaryngol Chir Cervicofac (1976) 0.75
[Anticoagulants with antithrombinase activity in systemic lupus erythematosus (author's transl)]. Nephrologie (1980) 0.75
[Current status of the preparation and use of antihemophilic fractions in France. (Their use in surgery in hemophilia)]. Transfusion (Paris) (1966) 0.75
[Specific anti-alpha 2 macroglobulin immune serum. Preparation and properties]. Rev Fr Transfus (1971) 0.75
[Circulating anticoagulants during hemophilia]. Rev Fr Transfus (1972) 0.75
Isolation and partial characterization of a human prothrombin variant: prothrombin Barcelona. Biochem Biophys Res Commun (1974) 0.75
[Nephrotic syndrome, antithrombin III deficiency and recurrent thrombosis. The value of vitamin K antagonists]. Arch Fr Pediatr (1979) 0.75
The P.P.S.B. fraction. Bibl Haematol (1970) 0.75
Activation of prothrombin Barcelona. Evidence for active high molecular weight intermediates. Biochim Biophys Acta (1979) 0.75
Tissue factor activity of rabbit peritoneal macrophages: influence of immune stimulation. Ann Immunol (Paris) (1977) 0.75
[Therapeutic use of epsilon aminocaproic acid]. Sem Ther (1964) 0.75
[In-vitro "thromboplastic" activity of leukocytes and intravascular blood coagulation in leukemias]. Pathol Biol (Paris) (1972) 0.75
[Procedure to follow in the presence of a transfusion complication due to blood incompatibility]. Transfusion (Paris) (1965) 0.75
[Pathology of hemostasis in the newborn infant. Experiences during 3 years at the Hospital for Sick Children in Paris]. Nouv Rev Fr Hematol (1976) 0.75
[Thrombin, enzyme of hemostasis and thrombosis: a model of enzymatic autoregulation]. Pathol Biol (Paris) (1977) 0.75
[Effects of the Vipera aspis poison on the plasma factors of hemostasis]. C R Acad Sci Hebd Seances Acad Sci D (1970) 0.75
[Platelet hyperactivity associated with intravascular coagulation: experimental study in rabbits]. Rev Eur Etud Clin Biol (1971) 0.75
[Coagulation disorders during acute leukemias]. Rev Prat (1973) 0.75
[Role of medical advisers in the French Association of Hemophiliacs]. Bibl Haematol (1966) 0.75
[Physiology of blood coagulation]. Pathol Biol (Paris) (1970) 0.75
[Anticoagulant therapy: physiologic problems]. Acquis Med Recent (1970) 0.75
Preparation and clinical use of P.P.S.B. (factors II, VII, X and IX concentrate). Thromb Diath Haemorrh Suppl (1968) 0.75
[Consumption coagulopathies in new-born infants (8 cases)]. Arch Fr Pediatr (1971) 0.75
[Heparin inhibition of the antithrombin activity of alpha-2-macroglobulin]. C R Seances Acad Sci D (1979) 0.75
[The treatment of pain in hemophiliacs. Introduction]. Bibl Haematol (1966) 0.75
[Prospects of development of information technics in blood transfusion]. Bull Inst Natl Sante Rech Med (1971) 0.75
Intravascular coagulation and nephropathies. Adv Nephrol Necker Hosp (1974) 0.75
[Probable localisation of a Hageman (factor XII) locus on an autosome]. Ann Genet (1968) 0.75
[Are the androgens effective in the treatment of medullary aplasias?]. Presse Med (1967) 0.75
Heparin prevents thrombin inhibition by alpha 2 macroglobulin. Thromb Res (1980) 0.75
[Duration of life of the fibrin stabilizing factor (factor 13). Therapeutic indications]. Transfusion (Paris) (1966) 0.75
[Study of the coagulation with measurement of the catabolism of marked fibrinogen in Moschkowicz's disease]. Ann Pediatr (Paris) (1969) 0.75
[The system Hemalog D in paediatrics (author's transl)]. Nouv Rev Fr Hematol (1978) 0.75
[Control of accuracy in hemacytometry based on the daily average of patients' tests. A rational method by simulating the detectable error (proceedings)]. Nouv Rev Fr Hematol Blood Cells (1978) 0.75
[Injections of tissue extracts and autologous hemolysates in the dog. Effects on the factors of hemostasis]. Nouv Rev Fr Hematol (1968) 0.75
A new variant of human prothrombin: prothrombin Metz, demonstration in a family showing double heterozygosity for congenital hypoprothrombinemia and dysprothrombinemia. Haemostasis (1982) 0.75
The action of Vipera aspis venom on blood clotting factors and platelets. Thromb Diath Haemorrh (1972) 0.75
[Global coagulability in vitro of capillary blood. Applicaton to the jurveillance heparin therapy in children]. Pathol Biol (Paris) (1974) 0.75
[Surgery in hemophilics: principles of conducting substitutive treatment]. Hemostase (1965) 0.75
Fibrinogen Bondy: a new case of dysfibrinogenemia. Isolation of the abnormal fibrinogen molecules. Thromb Res (1982) 0.75
[Presence of a plasma antigen indispensable to the stabilization of fibrin in 2 cases on congenital factor XIII deficiency]. Thromb Diath Haemorrh (1970) 0.75
[Experimental defibrination syndromes]. Nouv Rev Fr Hematol (1968) 0.75
[Can one measure in vitro the efficacy and toxicity of antilymphocyte serum?]. Presse Med (1970) 0.75
[Antiplasmin, antitrypsin and antithrombin activity of alpha-2-macroglobulin]. Transfusion (Paris) (1967) 0.75
[The treatment of hematurias in hemophiliacs: study of 62 cases in 40 hemophiliacs]. Bibl Haematol (1966) 0.75
[Hematologic disorders observed in patients following renal transplantation]. Nouv Rev Fr Hematol Blood Cells (1977) 0.75
Human prothrombin: a new method of preparation from a single individual. Thromb Diath Haemorrh (1973) 0.75
The therapeutic use of fraction P.P.S.B. Bibl Haematol (1968) 0.75
Factor V and VIII activation "in vivo" during bleeding. Evidence of thrombin formation at the early stage of hemostasis. Pathol Biol (Paris) (1976) 0.75
Hereditary hypoprothrombinaemia. True deficiency of factor II. Acta Haematol (1972) 0.75
Thrombin Metz: characterization of the dysfunctional thrombin derived from a variant of human prothrombin. Blood (1984) 0.75
[Repeated voluntary poisoning with phenyl-indane-dione (pindione)]. Nouv Rev Fr Hematol (1967) 0.75
[On coagulation and catabolism of labelled fibrinogen during Moschkowicz's disease]. Arch Fr Pediatr (1969) 0.75
[Procedure to follow in the presence of a transfusion accident due to blood incompatibility]. Anesth Analg (Paris) (1966) 0.75
[Drug-induced hemolysis]. Presse Med (1968) 0.75
[Relationship between hemolytic action and lecithinase activity of Naja nigricollis venom]. C R Acad Sci Hebd Seances Acad Sci D (1969) 0.75
[Disseminated intravascular coagulation in 49 patients with acute kidney failure]. J Urol Nephrol (Paris) (1972) 0.75
Treatment of deficiencies in factors II, VII and X. General review. Bibl Haematol (1965) 0.75
[Systematic follow up of "asymptomatic" monoclonal dysglobulinemias in blood donors]. Rev Fr Transfus (1968) 0.75
[Unusual leukemic syndrome in a newborn with 21 trisomy: megakaryocyte and platelet proliferation; disseminated intravascular coagulation syndrome]. Nouv Rev Fr Hematol (1974) 0.75
[Influence of the hematocrit on the formation of Heinz bodies within the red cells (author's transl)]. Ann Biol Clin (Paris) (1978) 0.75
[Constitutional and acquired dysprothrombinemias]. Nouv Rev Fr Hematol (1971) 0.75
Tentative immunochemical analysis of the prothrombin molecule. Pathol Biol (Paris) (1972) 0.75
Respective roles of antithrombin III and alpha 2 macroglobulin in thrombin inactivation. Thromb Haemost (1981) 0.75
[Toxicity and secondary effects of antilymphocyte serums]. J Urol Nephrol (Paris) (1969) 0.75